Notably, similar to its active form RAB22AQ64L, some RAB22A mutants detected in human cancers, such as D31H, D31Y, P32S, M43I, V84L, S94I, R104Q, and E127Q, were more effective in increasing LC3-II in cells and inducing Refeesomes containing active STING compared to RAB22AWT (Supplementary information, Fig. S9a, b), and these mutants also promoted STINGV155M secretion via EVs at the similar level compared with RAB22AQ64L (Supplementary information, Fig. S9c), suggesting that cancer patients harboring these RAB22A mutants may benefit more from chemoradiotherapy. The gene discussed is RAB22A; the disease is cancer.